Surgical tech company Elucent Medical lands US $30M investment

USA – Elucent Medical, a company specializing in guided surgical technology, has secured US $30 million in growth capital from Trinity Capital.

This funding is aimed at scaling its operations and advancing both innovation and commercialization efforts for its flagship product, the EnVisio System.

The EnVisio System utilizes a spatial field generator that measures continuous data points across multiple planes to deliver precise 3D positioning of its SmartClip marker and SmartSensor.

These technologies guide soft-tissue surgical excision with exceptional accuracy. CEO Jason Pesterfield expressed enthusiasm about the company’s progress, stating, “Our EnVisio System gives surgeons confidence before, during, and after their surgical procedures so they know they have delivered unparalleled accuracy and precision for their patients.”

He added, “We are in scale mode and are excited to partner with Trinity Capital. Trinity Capital’s investment will be key to our continued acceleration of our innovation and commercialization efforts.”

Elucent Medical has been steadily expanding its presence in the medtech field. Earlier in 2024, the company raised US $44 million in a Series C funding round, demonstrating significant investor confidence in its technology and vision.

The field of surgical innovation continues to grow with other notable players making advancements.

MediViewXR, for instance, employs augmented reality (AR) to develop extended reality surgical navigation for procedures such as tumor ablation and biopsy.

In collaboration with GE HealthCare, MediViewXR successfully introduced the OmnifyXR Interventional Suite System, which integrates GE’s imaging technology with MediView’s AR surgical platform.

This system allows physicians to better understand patient anatomy, make more informed clinical decisions, and collaborate remotely with care teams.

Another competitor, Proprio, raised US $43 million in Series B funding in 2023. The company’s surgical navigation platform, Paradigm, combines light field technology and artificial intelligence to generate real-time 3D visualizations during surgery.

Proprio also offers Volumetric Intelligence, a platform that merges medical images with data from Paradigm’s sensors.

Boston-based Activ Surgical is also pushing the boundaries of surgical innovation. The company’s platform leverages computer vision, artificial intelligence, analytics, and machine learning to enhance intraoperative decision-making and reduce surgical complications.

Activ Surgical’s focus on digital surgery has attracted significant funding, including a US $45 million Series B round in 2021.